Formulated for hypercholesterolemia to target elevated lipid levels and support cardiovascular health.
Mechanism of Action
This agent competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate. This action increases LDL receptors on hepatocyte surfaces, enhancing the uptake and catabolism of circulating LDL cholesterol.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24–48 hours
Contraindications
Active liver disease, Hypersensitivity to rosuvastatin, Pregnancy, Breastfeeding
Information related to Crestor is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
